A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors

Mutant-specific inhibitors of KRAS(G12C), such as AMG510 (sotorasib) and MRTX849 (adagrasib), offer the unprecedented opportunity to inhibit KRAS, the most frequently mutated and heretofore undruggable oncoprotein. While clinical data are still limited, on-target mutations in KRAS(G12C) at position...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Siyu, Callow, Marinella G., Fortin, Jean-Philippe, Khan, Zia, Bray, David, Costa, Mike, Shi, Zhen, Wang, Weiru, Evangelista, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170150/
https://www.ncbi.nlm.nih.gov/pubmed/35471904
http://dx.doi.org/10.1073/pnas.2120512119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170150/
https://www.ncbi.nlm.nih.gov/pubmed/35471904
http://dx.doi.org/10.1073/pnas.2120512119

Ejemplares similares